Effect of Intraoperative Platelet-Rich Plasma Treatment on Postoperative Donor Site Knee Pain in Patellar Tendon Autograft Anterior Cruciate Ligament Reconstruction: A Double-Blind Randomized Controlled Trial

Abstract

Background:

Donor site morbidity in the form of anterior knee pain is a frequent complication after bone–patellar tendon–bone (BPTB) autograft anterior cruciate ligament (ACL) reconstruction.

Hypothesis/Purpose:

The purpose was to examine the effect of the intraoperative administration of platelet-rich plasma (PRP) on postoperative kneeling pain. It was hypothesized that PRP treatment would reduce knee pain.

Study Design:

Randomized controlled trial; Level of evidence, 2.

Methods:

Fifty patients (mean ± SD age, 30 ± 12 years) undergoing BPTB ACL autograft reconstruction were randomized to the PRP (n = 27) or sham (n = 23) treatment. In either case, 10 mL of venous blood was drawn before the induction of anesthesia and either discarded (sham) or processed (PRP) for preparation of a PRP gel to be later mixed with donor site bone chips and inserted into the patellar defect. At 12 weeks, 6 months, 1 year, and 2 years after surgery, patients completed International Knee Documentation Committee (IKDC) forms and visual analog scale pain scores for activities of daily living and kneeling. Healing indices at the donor site were assessed by routine noncontrast magnetic resonance imaging (MRI) at 6 months. Mixed-model analysis of variance was used to assess the effect of PRP on patient symptoms and MRI indices of donor site healing, as measured by the width of the donor site defect.

Results:

Kneeling pain, pain with activities of daily living, and IKDC scores were not different between treatment groups at any of the time intervals (P = .08-.83). Kneeling pain improved from 12 weeks to 6 months and from 1 to 2 years (P < .05). IKDC scores improved substantially from 12 weeks to 6 months (P < .001) and continued to improve to 2 years (PRP, 86 ± 19; sham, 89 ± 10). MRI indices of donor site healing were not different between treatment groups (P = .53-.90).

Conclusion:

Whether randomized to receive PRP in their patellar defect or not, patients continued to have similar levels of kneeling pain and patellar defect sizes after autograft BPTB ACL reconstruction.

Registration:

NCT01765712 (ClinicalTrials.gov identifier).